”completion of this Phase I trial, NYR-BI03 has the potential to progressdirectly to Phase II trials to assess its efficacy in stroke, traumatic brain injury, and nowmyocardial ischemia-reperfusion injury.”
So this phase 1 about to start shortly takes us straight to phase 2 in myocardial ischemia-reperfusion injury. We don’t need to do another phase 1. Now that’s what I like to hear. GLP micronucleus results are the big ones from GLP and the last ones to be announced shortly to heavily de risk safety.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.03M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1642 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 682527 | 2 |
View Market Depth
| Last trade - 14.40pm 31/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable